Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Hybridoma Technology

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Timing of Treatment for Ruptured Cerebral Aneurysms: Impact on Clinical Outcome. A Case Series from a Tertiary Center.

World neurosurgery·2025

Same author

A novel throughput assay to assess molecular hydrophobicity during early biotherapeutic developability assessments.

mAbs·2025

Same author

Temperature and excipient mediated modulation of monoclonal antibody interactions revealed by <i>k</i>D, rheology, and Raman spectroscopy.

mAbs·2025

Same author

Deep learning-based design and experimental validation of a medicine-like human antibody library.

Briefings in bioinformatics·2025

Same author

αFAP-specific nanobodies mediate a highly precise retargeting of modified AAV2 capsids thereby enabling specific transduction of tumor tissues.

Molecular therapy. Methods & clinical development·2024

Same author

Human antibody polyreactivity is governed primarily by the heavy-chain complementarity-determining regions.

Cell reports·2024

Search research articles

Related Experiment Video

Updated: Jul 8, 2025

Generation of Discriminative Human Monoclonal Antibodies from Rare Antigen-specific B Cells Circulating in Blood

Generation of Discriminative Human Monoclonal Antibodies from Rare Antigen-specific B Cells Circulating in Blood

Published on: February 6, 2018

Matrixed CDR grafting: A neoclassical framework for antibody humanization and developability.

Pankaj Gupta¹, Alexander M Horspool¹, Goral Trivedi¹

¹Biotherapeutics Discovery, Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, Connecticut, USA.

The Journal of Biological Chemistry

|December 10, 2023

Summary

This summary is machine-generated.

Humanizing antibodies involves balancing target binding and developability. This study shows that optimizing antibody frameworks, not just sequence homology, yields better biotherapeutic candidates with improved properties for faster development.

Keywords:

CDR grafting biophysical assessment developability germlines humanization

More Related Videos

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction

Published on: September 14, 2018

Generation of Murine Monoclonal Antibodies by Hybridoma Technology

Generation of Murine Monoclonal Antibodies by Hybridoma Technology

Published on: January 2, 2017

Related Experiment Videos

Last Updated: Jul 8, 2025

Generation of Discriminative Human Monoclonal Antibodies from Rare Antigen-specific B Cells Circulating in Blood

Generation of Discriminative Human Monoclonal Antibodies from Rare Antigen-specific B Cells Circulating in Blood

Published on: February 6, 2018

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction

Published on: September 14, 2018

Generation of Murine Monoclonal Antibodies by Hybridoma Technology

Generation of Murine Monoclonal Antibodies by Hybridoma Technology

Published on: January 2, 2017

Area of Science:

Biotechnology
Immunology
Protein Engineering

Background:

Developing biotherapeutic monoclonal antibodies requires balancing target engagement with physicochemical properties.
Humanization of nonhuman antibodies is crucial for leveraging diverse antibody discovery platforms.
Traditional humanization focused on germline homology, often neglecting molecular properties.

Purpose of the Study:

To assess the impact of different human variable region framework sequences on antibody developability and function.
To evaluate complementary determining region-framework compatibility beyond maximal sequence homology.
To identify humanized antibody variants with improved global properties for biotherapeutic development.

Main Methods:

Grafting mouse anti-LAG3 antibody complementary determining regions (CDRs) into diverse human variable heavy (VH) and variable light (VL) framework libraries.
Progressive evaluation of expression, affinity, biophysical developability, and function of grafted antibodies.
Utilizing principal component analysis to assess multiple graft-framework combinations.

Main Results:

Specific VH and VL framework sequences significantly impacted expression and purification.
Greater VL sequence conservation correlated with retained or improved binding affinity.
VH influenced developability, while VL affected cell binding and function; some non-optimally conserved grafts showed superior properties.

Conclusions:

Modern high-throughput systems allow systematic analysis of CDR-framework combinations.
Humanized antibodies with improved global properties can be generated by optimizing framework selection beyond sequence homology.
This approach enhances the probability of successful biotherapeutic antibody development.